US Patent

US7173037 — Carbamate-substituted pyrazolopyridines

Composition of Matter · Assigned to Bayer Healthcare AG · Expires 2026-12-04 · 1y remaining

Vulnerability score 27/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects compounds that stimulate soluble guanylate cyclase, which are used as medicaments for treating cardiovascular disorders and/or sexual dysfunction.

USPTO Abstract

The present invention relates to compounds which stimulate soluble guanylate cyclase, to the preparation thereof and to the use thereof as medicaments, in particular as medicaments for the treatment of cardiovascular disorders and/or sexual dysfunction.

Drugs covered by this patent

Patent Metadata

Patent number
US7173037
Jurisdiction
US
Classification
Composition of Matter
Expires
2026-12-04
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Bayer Healthcare AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.